by Nassir Ghaemi | Feb 2, 2022 | Blog posts
Summary of the canon of psychopharmacology So what does the canon of psychopharmacology teach us? An important lesson is that even though the studies were conducted outside the realm of the pharmaceutical industry, by academic centers and with government funding, in...
by Nassir Ghaemi | Feb 2, 2022 | Blog posts
The conventional wisdom: STEP-BD for bipolar depression CATIE was the largest (about 1500 patients) and most ambitious of the three canons of psychopharmacology; it failed to show that most patients even stay on their medications for a year in schizophrenia. STAR*D...
by Nassir Ghaemi | Jan 21, 2022 | Blog posts
The conventional wisdom: STAR*D for depression The second large canon of psychopharmacology is the STAR*D study, a large sequential large randomized clinical trial (RCT) of over 1000 patients with an acute depressive episode of so-called major depressive disorder...
by Nassir Ghaemi | Jan 12, 2022 | Blog posts
The conventional wisdom: CATIE for schizophrenia Here is the official line on the design and results of this study: CATIE was a one year study of schizophrenia, in which a large sample of about 1500 patients were recruited at about 50 clinical trial sites (exact...
by Nassir Ghaemi | Jan 11, 2022 | Blog posts
In the mid-1990s, an incredible thing happened. The National Institute of Mental Health (NIMH) decided to fund major clinical psychopharmacology studies. About 90% of NIMH is for other purposes, so the world of clinical psychopharmacology always has suffered from...
